Clinical, Biological, and Laboratory Parameters as Predictors of Severity of Clinical Outcome and Response to Anti–TNF–Alpha Treatment in Ulcerative Colitis

Olsen, Trine; Florholmen, Jon

doi:10.5772/28096

Cited by 1 publication

(2 citation statements)

References 106 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identifying factors predictive of the efficacy of IFX in patients with refractory UC is clinically important. Among the factors previously reported to predict clinical responses to IFX treatment in UC patients are hemoglobin concentration, serum albumin concentration, disease activity, normalization of serum CRP concentration after IFX induction, and the trough of IFX [ 7 , 9 , 17 , 21 - 23 ]. We found that serum CRP concentration <5 mg/L 2 weeks after initiating IFX was predictive of a clinical response to IFX in patient with refractory UC.…”

Section: Discussionmentioning

confidence: 99%

“…We found that serum CRP concentration <5 mg/L 2 weeks after initiating IFX was predictive of a clinical response to IFX in patient with refractory UC. Biomarkers such as CRP, fecal calprotectin, and fecal lactoferrin have been reported to act as surrogate markers of mucosal inflammation in patients with inflammatory bowel disease [ 23 - 25 ], with CRP being a particularly sensitive marker in UC patients. Thus, early reduction of serum CRP may be a useful marker for evaluating the efficacy of IFX treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

et al. 2014

View full text Add to dashboard Cite

BackgroundThe long-term efficacy of infliximab (IFX) for patients with refractory ulcerative colitis (UC) is unclear. The aim of this study was to assess the long-term outcomes of IFX treatment in patients with refractory UC.MethodsThirty-three patients with refractory UC who received IFX treatment at Kyoto University Hospital between 2003 and 2013 were retrospectively evaluated. IFX intensification was defined as a dose escalation (up to 10 mg/kg) and/or shorter intervals between infusions (every 4–6 weeks).ResultsOf the 33 patients who received scheduled infusions of IFX, 24 (72.7%) achieved clinical remission within 8 weeks after initiating IFX treatment. Of these 24 responders, 17 (70.8%) experienced a relapse of UC and required IFX intensification, and 16 (66.7%) eventually maintained clinical remission with IFX treatment, including IFX intensification. Of the 33 patients, 6 (18.2%) underwent colectomy during IFX treatment. Multivariate regression analysis showed that a serum C-reactive protein (CRP) concentration <5 mg/L two weeks after starting IFX was a predictor of a positive clinical response to IFX induction therapy. No severe adverse events occurred in UC patients treated with IFX.ConclusionIFX intensification was necessary for long-term maintenance of remission and to prevent colectomy in patients with refractory UC.

show abstract